Moreover, combination therapy employing NK cells pre-activated with dendritic cells and the TLR7/8 agonist gardiquimod (GDQ) significantly suppresses the growth of human HepG2 liver carcinoma xenografts (149). Here, TLR7 is linked to hepatocellular carcinoma.